Prognostic factors of oncologic and reproductive outcomes in fertility-sparing management of endometrial atypical hyperplasia and adenocarcinoma: systematic review and meta-analysis-Reference-Cited by-同舟云学术

Prognostic factors of oncologic and reproductive outcomes in fertility-sparing management of endometrial atypical hyperplasia and adenocarcinoma: systematic review and meta-analysis

Published:2014-03 Issue:3 Volume:101 Page:785-794.e3
ISSN:0015-0282
Container-title:Fertility and Sterility
language:en
Short-container-title:Fertility and Sterility

Author:

Koskas Martin,Uzan Jennifer,Luton Dominique,Rouzier Roman,Daraï Emile

Publisher

Elsevier BV

Subject

Obstetrics and Gynaecology,Reproductive Medicine

Reference40 articles.

1. Young patients with endometrial cancer: how many could be eligible for fertility-sparing treatment?;Navarria;Gynecol Oncol,2009

2. Safety of uterine and/or ovarian preservation in young women with grade 1 intramucous endometrial adenocarcinoma: a comparison of survival according to the extent of surgery;Koskas;Fertil Steril,2012

3. Oncologic and reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 adenocarcinoma: a systematic review;Gunderson;Gynecol Oncol,2012

4. Multicenter phase II study of fertility-sparing treatment with medroxyprogesterone acetate for endometrial carcinoma and atypical hyperplasia in young women;Ushijima;J Clin Oncol,2007

5. Evaluating the association between endometrial cancer and polycystic ovary syndrome;Haoula;Hum Reprod,2012

Cited by 154 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Outcomes of extended progestin therapy in atypical endometrial hyperplasia patients without an initial response to progestin: a retrospective study from two tertiary centers in Korea and Taiwan;Journal of Gynecologic Oncology;2025

2. Advantages of Robotic Surgery for Patients of Reproductive Age with Endometrial Cancer;Life;2024-09-03

3. A multi-centre randomised controlled trial comparing megestrol acetate to levonorgestrel-intrauterine system in fertility sparing treatment of atypical endometrial hyperplasia;Journal of Assisted Reproduction and Genetics;2024-08-31

4. Update on the oncologic and obstetric outcomes of medroxyprogesterone acetate treatment for atypical endometrial hyperplasia and endometrial cancer;Journal of Obstetrics and Gynaecology Research;2024-08-02

5. Mismatch repair deficiency and abnormal p53 expression has significant predictive value for progesterone resistance and endometrial tumorigenesis in patients with endometrial atypical hyperplasia receiving fertility-preserving treatment;Gynecologic Oncology;2024-07